ClinicalTrials.gg
RecruitingNCT06298929Updated Mar 7, 2024

Medial Rectus Fenestration vs Recession for PAET

An interventional study of medial rectus fenestration and medial rectus recession in Partially Accommodative Esotropia, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2024-03-07.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2023, registered Feb 2024).
  • Started Nov 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

This prospective comparative study aims to compare medial rectus (MR) muscle fenestration and recession in patients with partially accommodative esotropia (PAET). The main question it aims to answer is whether MR fenestration is equally effective as MR recession for PAET.

All patients will receive complete ophthalmic and orthoptic assessment. Patients will be randomly allocated using a random table to one of two groups; Group 1 will receive conventional MR recession, and Group 2 will receive MR fenestration.

Read the detailed description

Inclusion criteria The study will include patients with accommodative esotropia if the residual distance deviation with full cycloplegic correction is > 15PD.

Exclusion criteria:

  1. Patients with convergence excess esotropia, defined as a near deviation with glasses exceeding that for distance by 15 PD or more.
  2. Patients with paralytic or restrictive strabismus.
  3. Patients with previous strabismus surgery
  4. Patients with neurologic, ocular, or developmental disorders or follow-up less than 6 months

All patients will receive complete ophthalmic and orthoptic assessment including:

i) A full ophthalmological assessment including history taking, measurement of uncorrected and best-corrected visual acuity, cycloplegic refraction, anterior segment examination, as well as a dilated fundus examination.

ii) Measurement of the deviation at distance (6 m) and near (33 cm). iii) Assessment of ductions and versions in all cardinal directions of gaze

Patients will be randomly allocated using a random table to one of two groups:

  1. Group 1: Unilateral or bilateral conventional MR recession. Augmented formula will be used to decide the Surgical dosage using the standard tables (3)
  2. Group 2: unilateral or bilateral MR fenestration All surgeries will be performed by one experienced surgeon (H.SH)
02

Conditions studied

  • Partially Accommodative Esotropia

Browse trials for

Keywords

  • esotropia
  • accommodative
  • hyperopia
  • recession
  • fenestration
03

In context

Esotropia

36 studies on the registry are indexed under Esotropia; 11 are open to participants now.

This study's planned enrollment of 60 is below the median of 78 across 23 interventional studies indexed under Esotropia.

Browse Esotropia studies →

Lead sponsor

Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with accommodative esotropia if the residual distance deviation with full cycloplegic correction is > 15PD.

Exclusion criteria

Exclusion Criteria:

  1. convergence excess esotropia.
  2. paralytic or restrictive strabismus.
  3. previous strabismus surgery
  4. neurologic, ocular, or developmental disorders or follow-up less than 6 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Group 1

    patients with PAET who will receive unilateral or bilateral MR fenestration

    Procedure: medial rectus fenestration

  • Active comparator
    Group 2

    patients with PAET who will receive unilateral or bilateral MR recession

    Procedure: medial rectus recession

Interventions

  • Proceduremedial rectus fenestration

    Fenestration technique involves making two splitting incisions by blunt dissection parallel to the muscle fibers on the superior and inferior borders of the muscle, leaving 1 mm of muscle fibers on each edge. The rectangular wide central part is excised from the insertion and between the two splitting incisions to a point back 5-8 mm depending on the angle of the esotropia.

  • Proceduremedial rectus recession

    recession is one of the gold standard weakening procedures that involves disinsertion of the muscle and re-suturing to the sclera at a more posterior location to decrease its contractile power.

06

What researchers measure

Primary outcomes

  1. Ocular alignment (measured in prism diopters)

    The distance and near angles of deviation, with and without glasses, and the angle disparity

    Time frame: 6 months postoperative

Secondary outcomes

  1. ocular motility

    ductions of both eyes (graded on a scale of nine points from -4 to +4)

    Time frame: 6 months postoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06298929
Collaborators
Tanta University
Responsible party
Ameera Gamal Abdelhameed (assistant professor of ophthalmology, Mansoura University) — Principal investigator
First posted
Mar 7, 2024
Start date
Nov 15, 2023
Primary completion
Sep 15, 2024 (estimated)
Completion
Oct 15, 2024 (estimated)
Last update
Mar 7, 2024

Study contacts

Ameera G Abdelhameed, MD
Contact
amiragamal287@mans.edu.eg
+201120090000
Ameera G Abdelhameed, MD
principal investigator · Assistant professor of ophthalmology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion